Seite auswählen

French pharmaceutical company Sanofi has entered into a EUR 130 million strategic alliance with fellow French company Oncodesign to find new kinase inhibitors for a variety of indications.

As part of the four year contract, Oncodesign will apply its proprietary Nanocyclix to provide a medicinal chemistry platform for the discovery and development of inhibitors against unknown kinase targets.

[ilink url=“″] Link zur Quelle ([/ilink]